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IMMUNOTHERAPY IMMEDIATELY FOLLOWING TRANSPLANTATION
FOR MULTIPLE MYELOMA: EARLY RECOVERY OF AGGRESSIVE CYTO-
TOXIC CELLS AND IMPROVED IMMUNE RESURGENCE
Meehan, K.P.1, Bengtson, E.1, Wu, J.-Y.1, Ely, P.1, Hill, J.M.1,
Szczepiorkowski, Z.M.1, Ernstoff, M.1 1Dartmouth Hitchcock Medical
Center, Lebanon, NH.
The high relapse rate for patients with myeloma following
autologous transplant stresses the critical need for innovative
therapies. A phase I/II trial evaluated early administration and
dose escalation of IL-2, with GM-CSF post-transplant. Mel-
phalan (200mg/m2) was followed by an autologous peripheral
blood progenitor cell transplant. IL-2 began on Day 0 and
continued for 4 weeks. GM-CSF (250mcg/m2/day) began on
day 5 and continued until engraftment. Fifteen of nineteen
patients completed therapy. No treatment-related deaths oc-
curred. The MTD of IL-2 was 6  105 IU/m2/day. IL-2 (1 
106 IU/m2/d) was not tolerated in 3 of 6 patients due to  grade
3 fatigue/diarrhea (n1) or supraventricular arrhythmia (n2).
IL-2 (6  105 IU/m2/d) was well tolerated by 12 of 13 patients.
Engraftment of neutrophils occurred on Day 13 (median; range
10-17 days) and platelets on Day 17 (median; range: 0-74 days).
When compared to pre-transplant values, on Day 21, there was
a marked increase in the number of CD3 T cells (p  0.02),
CD4 T cells (p  0.03), CD8 T cells (p  0.03),
CD8CD56 NKT cells (p  0.02) and a borderline increase
in CD56 NK cells (p  0.05). Cytotoxicity of patients’ pe-
ripheral blood mononuclear cells directed against myeloma cells
(RPMI 8226) was strikingly increased at 74%, when compared
to baseline (p  0.01). The uniqueness of this trial is the early
administration of IL-2 on the day of transplant, in combination
with GM-CSF, during the period of lymphodepletion, demon-
strating a marked increase in the number and function of early
cytotoxic effector T and NKT cells, without suppression of
engraftment. The enhanced immune recovery may translate
into an improved outcome. Current research is elucidating the
mechanism(s) of tumor cell killing in vivo and adding adoptive
cellular therapy in a novel clinical trial.
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EFFICACY AND TOXICITY OF A SECOND AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL TRANSPLANT FOR PATIENTS WITH RELAPSED OR
RECURRENT MULTIPLE MYELOMA
Patel, R.C.1,2, Burzynski, J.A.1,2, Ochoa-Bayona, J.L.1,2, Toro, J.1,2,
Greene, R.E.1,2, Freytes, C.O.1,2 1South Texas Veterans Health Care
System, San Antonio, TX; 2University of Texas Health Science Center,
San Antonio, TX.
Background: Randomized trials demonstrated autologous pe-
ripheral blood stem cell transplantation (APBSCT) prolongs over-
all survival in patients with multiple myeloma (MM). There is no
curative therapy and all patients eventually relapse. Small case
series demonstrated the feasibility of a 2nd APBSCT in patients
who have relapsed after an APBSCT. However, the toxicities
associated with a 2nd APBSCT have not been well described. We
report the toxicity and outcomes of a 2nd APBSCT compared with
the 1st APBSCT.
Methods: A retrospective case series of all MM patients who
received a 2nd APBSCT for relapsed or progressive disease after
prior APBSCT between 1/1/99 and 9/22/06. Patients who had a
2nd APBSCT within 100 days of the 1st APBSCT were excluded.
Twenty-ﬁve patients met study inclusion criteria. Response was
assessed via ABMTR/IBMTR criteria. Toxicity is reported as
Common Toxicity Criteria for Adverse Events version 3.
Results:Median age at 1st APBSCT was 54 (range 37-69) and 57
(range 40-72) at 2nd APBSCT. Median time between diagnosis and
1st APBSCT was 7 months (4-33). Median interval between the 1st
and 2nd APBSCT was 43 months (range 4-96). Patients received a
median of 2 (range 0-6) salvage chemotherapy regimens between
the 1st and 2nd APBSCT. Four patients had stem cells in storage for
their 2nd APBSCT. Remaining patients were mobilized with ﬁl-
grastim (57%) or ﬁlgrastim  chemotherapy (43%). Ninety-two
percent of patients received melphalan 200mg/m2 as the condition-
ing regimen for their 2nd APBSCT. Median time to neutrophil
engraftment was 10 (8-16) days vs. 11 (9-17) days and platelet
engraftment was 13 (9-26) days vs. 16 (12-105) days for the 1st and
2nd APBSCT, respectively. Response rates after the 2nd APBSCT
were 20% CR, 50% PR, and 25% SD. One patient died from
treatment-related mortality. With a median follow up of 12
months (range 1 to 67), 60% of patients are alive, 4 of them more
than 2 years after their 2nd APBSCT. We observed grade 3 or 4
toxicity in 56% of patients after the 1st APBSCT and in 52% after
the 2nd APBSCT. The most common grade 3 or 4 toxicities
include: nausea (9% vs. 4%), vomiting (9% vs. 9%), diarrhea (9%
vs. 9%), mucositis (13% vs. 13%), infection (22% vs. 17%), and
febrile neutropenia (39% vs. 48%).
Conclusion: A 2nd APBSCT for MM can be performed with
comparable toxicity to the 1st APBSCT. Seventy percent of eval-
uated patients had at least a PR and one-ﬁfth of patients had
prolonged survival after the 2nd APBSCT.
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PHASE I/II TRIAL OF BORTEZOMIB MAINTENANCE FOLLOWING AU-
TOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTA-
TION AS TREATMENT FOR INTERMEDIATE- AND ADVANCED-STAGE
MULTIPLE MYELOMA
Schiller, G.J.1, Sohn, J.P.2, Malone, P.1, Bartoni, K.1,
Habtemariam, B.1, Paquette, P.1, deVos, S.1, Territo, M.1 1David
Geffen UCLA School of Medicine, Los Angeles, CA; 2VA Greater Los
Angeles Healthcare Center, Los Angeles, CA.
15 pts (median age 55 y, range 37 - 73 y) with intermediate and
advanced stage myeloma were assigned to maintenance with
bortezomib beginning 3-4mos after autoPSCT following high-
dose melphalan (200 mg/sq.m.). Eligibility required post-tx
minimum ANC  1000 mm-3 and untransfused platelet count of
30,000 mm-3. 3 patients each were entered at 1 of 3 dose levels
of bortezomib (1.0, 1.3, and 1.6 mg/m2) given IV 1x weekly for
3 wks followed by a 1-wk rest constituting 1 treatment cycle for
a total of 8 cycles. To-date, 21 pts were considered eligible and
15 pts received at least 1 dose of maintenance. Reasons for not
proceeding to maintenance: ANC  1000 mm-3, serum creati-
nine  2mg/dl (2 pt each), and 4 additional pts unable to travel
to the treatment center. The median time from diagnosis to tx
was 8 mos (range, 4 to 19 mos), and the median t from auto tx
to the initiation of bortezomib maintenance was 4 mos. Protocol
adherence was excellent with only 1 pt missing the ﬁnal dose.
The DLT was determined to be 1.6 mg/m2 based on grade 3
diarrhea in two patients after 2 and 3 cycles of treatment,
respectively. All subsequent pts entered were treated at the
MTD of 1.3 mg/m2. Other, non-dose-limiting toxicities in-
cluded, fatigue (13 pts), anorexia (1 pt), nausea (6 pts), dizziness
(3 pts), headache (4 pts), peripheral neuropathy (8 pts), throm-
bocytopenia (7 pts), neutropenia (1 pt), dry cough (2 pts), upper
respiratory infection (3 pts), and Zoster reactivation (4 pts).
Disease assessment consisted of serum and urine PEP monthly
for all pts, and bone marrow aspiration quarterly for those with
nonsecretory myeloma; repeat bone surveys were required for
all patients 3, 9, 15, and 21 mos post tx. While 1 pt required
termination of study drug at the end of treatment cycle 8 due to
unacceptable side effects, no pts required termination of study
drug for disease progression. Six pts currently continue to be
followed every 3 mos for evidence of disease recurrence in the
post-treatment period; others continue on treatment. This
phase I/II trial demonstrates that bortezomib can be safely
administered as a maintenance treatment following conven-
tional autologous peripheral blood progenitor cell transplanta-
tion with a maximum tolerated dose of 1.3 mg/m2 given three
times per month for eight months; treatment consolidated the
remission achieved by autologous transplant in 4/7 evaluable
pts. Further study will determine the impact of bortezomib
maintenance on recurrence.
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